Related Experiment Video

Updated: May 22, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Are calcineurin inhibitors-free regimens ready for prime time?

Flavio Vincenti1

  • 1University of California, San Francisco, Kidney Transplant Service, San Francisco, California 94143-0780, USA. Flavio.Vincenti@ucsfmedctr.org

Kidney International
|May 25, 2012
PubMed

Insights

New biologic therapies, like belatacept, offer safer immunosuppression for organ transplant patients, moving away from toxic calcineurin inhibitors (CNIs) and improving long-term graft survival.

Area of Science:

  • Transplant Therapeutics
  • Immunosuppression Strategies
  • Graft Survival

Background:

  • Calcineurin inhibitors (CNIs) cause toxicities like nephrotoxicity, limiting long-term transplant success.
  • While short-term graft survival improved, long-term outcomes remain modest due to drug toxicities.
  • The development of CNI-free regimens is crucial for safer, more effective immunosuppression.

Purpose of the Study:

  • To evaluate the impact of novel immunosuppression strategies, particularly belatacept, in transplant therapeutics.
  • To explore the potential of CNI-free regimens for durable engraftment without toxicities.
  • To assess the role of belatacept and other biologics in advancing transplant outcomes.

Main Methods:

  • Review of current immunosuppression strategies and their associated toxicities.
  • Analysis of the mechanism of action for belatacept (costimulation blockade).
  • Discussion of emerging biologics (e.g., ASKP1240, tofacitinib) for CNI-free regimens.

Main Results:

  • Belatacept offers a new paradigm in immunosuppression, providing effective T-cell activation blockade without CNI-related renal or cardiovascular toxicities.
  • The approval of belatacept marks a significant shift towards CNI-free immunosuppression in renal transplantation.
  • Novel agents like ASKP1240 and tofacitinib show promise for further advancing CNI-free transplant therapies.

Conclusions:

  • Belatacept represents a safe and effective CNI-free immunosuppression option, improving transplant outcomes.
  • The shift to biologic therapies like belatacept is poised to make CNI-free regimens standard practice.
  • Future research into novel biologics will continue to refine CNI-free strategies for organ transplantation.

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...